NASD · Healthcare · Biotechnology · USA
Agenus Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Agenus is a clinical-stage biotechnology firm creating treatments to harness immune system responses against cancer and infectious diseases. The company's primary focus is developing two complementary antibodies, botensilimab and balstilimab, tested across multiple malignancies including colorectal cancer, sarcoma, and ovarian cancer. Agenus also holds equity stakes in MiNK Therapeutics and maintains majority ownership of SaponiQx, a vaccine adjuvant business.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Agenus Inc stock.
Undervalued: intrinsic value $10.25 per share, market price $6.21, margin of safety 39.4% (as of 2026-11-17).
A 3.5x revenue multiple, discounted for its losses, values the shares at $10.25; the price of $6.21 is 39% below that value.
11 more funds hold it; the full list is part of the paid plan.
8 more in this industry show a wider margin of safety.
AGEN is undervalued (as of the 2026-11-17 close). A 3.5x revenue multiple, discounted for its losses, values the shares at $10.25; the price of $6.21 is 39% below that value.
$10.25 per share (as of the 2026-11-17 close), against a market price of $6.21. That is a margin of safety of 39.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.